DSGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Design Therapeutics Inc (DSGN) is not a strong buy for a beginner, long-term investor at this time. The stock lacks immediate positive catalysts, and its technical and financial performance does not suggest a compelling entry point. While there is potential upside in the long term based on its pipeline, the current price trend and lack of significant recent developments make it better suited for monitoring rather than immediate investment.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 42.059, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 9.972), with resistance at R1: 10.95. Overall, the technical indicators do not suggest a strong buy signal.
Hedge funds are increasing their positions, with a 108.37% increase in buying over the last quarter. Analysts have a positive long-term outlook, with Oppenheimer assigning an Outperform rating and an $18 price target, citing potential game-changing developments in the company's drug pipeline.
No recent news or significant insider activity. The company's financials show no revenue and a negative net income of -$16.997 million in Q3 2025, despite slight YoY improvement. Technical indicators suggest bearish momentum, and the stock has a higher probability of declining in the next week and month.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$16.997 million, which improved by 30.36% YoY. EPS also improved to -0.3 (up 30.43% YoY), but gross margin remains at 0%. The financials indicate the company is still in its early stages with no profitability.
Oppenheimer initiated coverage with an Outperform rating and an $18 price target. The firm is optimistic about the company's drug pipeline, particularly its lead program for Friedreich's ataxia, which could be a significant long-term catalyst. However, the major readout is expected in the second half of 2026, making it a long-term play rather than an immediate opportunity.
